Twitter & Facebook has banned this story

Inside Hunter Biden’s murky history of business dealings in China

https://nypost.com/2020/10/14/inside-hunter-bidens-murky-history-of-business-dealings-in-china/

An expose of Hunter Biden’s emails published by The Post on Wednesday showed the oft-troubled son leveraging access to his then-vice president father and introducing him to an executive of a Ukrainian gas company that was under scrutiny at the time.

The family’s dealings in Ukraine are the subject of several congressional probes and even led to the impeachment of President Trump who was eventually cleared in the Senate of the charge that he pressured Ukraine’s leader to dig up dirt on Joe Biden.

Hunter Biden’s dealings in China, however, have earned a lot less scrutiny — including over a $1 billion windfall for his business venture just days after visiting Beijing with his influential father.

In 2009, Hunter Biden and Christopher Heinz, the stepson of former secretary of state John Kerry, founded Rosemont Seneca Partners, a billion-dollar private equity firm.

Still at the helm of the firm, Hunter flew aboard Air Force Two to China in December 2013, accompanying his then-veep father on an official visit where Joe Biden reportedly met with Hunter’s Chinese partners.

Ten days later, Hunter’s company inked a deal with the state-owned Bank of China and created the $1 billion investment fund called Bohai Harvest RST (BHR), according to reporting by Peter Schweizer, president of the Government Accountability Institute and the best-selling author of “Secret Empires: How the American Political Class Hides Corruption and Enriches Family and Friends.”

A representative for BHR told The New Yorker in July 2019 that Hunter Biden introduced his father to Chinese private equity executive Jonathan Li during the trip. Li later became the CEO of BHR.

Hunter Biden was forced to step down from the BHR board in October 2019 following blistering call outs from President Trump.

A spokesman for Biden’s family denied any wrongdoing or that there was a connection between the vice president’s visit and BHR’s wild fundraising success.

However, Schweizer found what he described as “a troubling pattern” of Biden and Heinz both seeming to benefit from their fathers’ positions in the Obama administration.

“Over the next seven years, as both Joe Biden and John Kerry negotiated sensitive and high-stakes deals with foreign governments, Rosemont entities secured a series of exclusive deals often with those same foreign governments,” Schweizer wrote in his book.

In another May 2017 incident, Hunter met with Chinese tycoon Ye Jianming, the chairman of energy company CEFC, in a Miami hotel room and the pair discussed American infrastructure and energy deals, according to a 2018 report by the New York Times.

After the meeting, Ye sent Hunter a 2.8-carat diamond and a “thank you” note and the ex-veep’s son began negotiating a deal for CEFC to invest $40 million dollars in a natural gas project on Louisiana’s Monkey Island.

Six months later, a CEFC executive was arrested in New York on unrelated bribery charges, and his first call was to Hunter Biden’s uncle, James Biden. According to the Times report, James believed the call was for Hunter.

“There is nothing else I have to say,” James Biden told the publication. “I don’t want to be dragged into this anymore.”

 

Cancer pts: 2013 to 2017, the national opioid prescribing rate declined by 20.7% among oncologists and 22.8% among non-oncologists

Opioid Prescribing for Cancer Care Drops

https://www.drugtopics.com/view/opioid-prescribing-for-cancer-care-drops

The rate of prescribing opioids among both oncologists and non-oncologists has dropped significantly in the past few years, raising concerns for patient care, according to a recent study.

In the wake of the US opioid epidemic, there have been major efforts to curb opioid prescribing. Researchers at Yale University School of Medicine set out to discover whether the efforts have affected prescribing among oncologists, whose patients often require opioids for symptom management.

Their findings, recently published in the Journal of the National Cancer Institute, showed that, from 2013 to 2017, the national opioid prescribing rate declined by 20.7% among oncologists and 22.8% among non-oncologists.1

During the 5-year period, 43 states reported a decrease in opioid prescribing among oncologists. In 5 states, opioid prescribing decreased more among oncologists than non-oncologists, according to the study.

From 2013 to 2017, prescribing of gabapentin increased by 5.9% among oncologists and 23.1% among oncologists and non-oncologists, respectively. Among palliative care providers, opioid prescribing increased by 15.3%.

“Given similar declines in opioid prescribing among oncologists and non-oncologists, there is concern that opioid prescribing guidelines intended for the non-cancer population are being applied inappropriately to patients with cancer and survivors,” wrote Vikram Jairam, MD, with the department of therapeutic radiology at Yale University School of Medicine.

It is reasonable to assume that the steep drop in opioid prescribing rates among oncologists is related to the “seismic shifts in prescribing regulations and attitudes toward opioids,” wrote Andrea C. Enzinger, MD, and Alexi A. Wright, MD, MPH, both with the Dana-Farber Cancer Institute in Boston, Massachusetts , in a companion editorial.

“The period studied overlaps with the rapid expansion of state opioid legislation establishing prescription drug monitoring programs (PDMPs), mandating provider education, and requiring patient identification and pharmacist verification prior to opioid dispensing,” they wrote. “Prescription drug plans also began imposing limits on the quantity, dose, or duration of opioid prescriptions, further reducing prescribing.”

Writing an opioid prescription has become a complex process that involves signing controlled substance agreements, checking PDMPs, filling prior authorization paperwork, communicating with pharmacists, and “even rewriting prescriptions to comply with seemingly arbitrary and sometimes conflicting rules set by states, insurers, and pharmacies,” Enzinger and Wright wrote.

“These burdens likely disincentivized oncologists from prescribing, potentially shifting this responsibility to palliative care — as evidenced by the 15% increase in opioid prescribing observed among palliative care physicians,” they wrote. “To protect cancer patients’ access, it is critical for policy solutions to lessen — rather than add to — oncology providers’ workload.”

Pharma files for bankruptcy because of various opiate crisis lawsuits

Mallinckrodt files for Chapter 11 bankruptcy

https://www.beckershospitalreview.com/pharmacy/mallinckrodt-files-for-chapter-11-bankruptcy.html

Mallinckrodt has filed for Chapter 11 bankruptcy for all of its U.S. subsidiaries and some international subsidiaries, the company said Oct. 12. 

The bankruptcy restructuring will reduce the company’s total debt by about $1.3 billion and resolve opioid-related claims and litigation involving its drug Acthar.

“After many months of deliberation, negotiation and consideration of alternatives, Mallinckrodt’s management and board of directors determined that implementing a Chapter 11 restructuring provides the best opportunity to maximize the value of the enterprise and position the company for the future in light of the current challenges it faces,” said Mark Trudeau, Mallinckrodt’s CEO. 

Opioid claims against the company are to be channeled into one or more trusts which would receive $1.6 billion in structured payments. The company also agreed to pay $260 million over seven years to settle claims it knowingly underpaid Medicaid for Acthar. 

In the bankruptcy filing, Mallinckrodt listed both assets and liabilities in the range of $1 billion to $10 billion. 

The company will continue to operate as normal as it restructures for bankruptcy. 

Mallinckrodt had said in February that it would put its U.S. generics business in bankruptcy as part of a proposed opioid settlement. In August, the company said it was considering bankruptcy for the parent company and most of its subsidiaries. 

In early March, the U.S. sued Mallinckrodt, alleging it knowingly underpaid Medicaid hundreds of millions of dollars in rebates for Acthar. The U.S. Justice Department said the company had calculated its rebate payments to Medicaid based on the drug’s price in 2013, but it has raised the drug’s price by 20 percent since then. The company was ordered to pay $650 million to CMS. 

As part of its bankruptcy filing, Mallinckrodt said it would reset Acthar’s Medicaid rebate calculation as of July 1, and that state Medicaid programs will receive 100 percent rebates on Acthar Medicaid sales. The company said it will dismiss its appeal of the Justice Department’s ruling in the case. 

Read Mallinckrodt’s full news release here.

Fewer people dying during the COVID-19 pandemic than two previous years ?

In the USA – on average 7500 people die EVERY DAY… according to this. According to this, total USA deaths for 2020 is projected to be the LOWEST IN THREE YEARS and this number must include the reported 200,000+ COVID-19 deaths.

Makes one wonder before the pandemic… reportedly we had a death crisis of opiate OD’s and vaping deaths.

 

US Blood Pressure Validated Device Listing

US Blood Pressure Validated Device Listing

https://www.validatebp.org/

Blood pressure measurement devices that have been validated for clinical accuracy as determined through an independent review process.

Uncontrolled high blood pressure (“BP”) is the leading risk factor for death and disability. The accurate measurement of BP is essential for the diagnosis and management of hypertension. One important aspect of accurate measurement is whether the BP measurement device has been validated for clinical accuracy.

To address this challenge, the American Medical Association (AMA) enlisted the National Opinion Research Center at the University of Chicago (NORC) to assist in the design and management of an independent process to determine which BP devices available in the U.S. meet the AMA’s established criteria to validate clinical accuracy (the “Validated Device Listing (VDL) Criteria”). An Independent Review Committee comprised of physician experts in the BP field assesses whether a BP device satisfies the VDL Criteria for validation of clinical accuracy. This independent review process results in a formal list of BP devices that have been validated for clinical accuracy (the “US Blood Pressure Validated Device Listing” or “VDL”).

More information regarding the VDL Criteria, governance structure, and requirements for BP device manufacturers to submit device documentation to the Independent Review Committee can be found on the Validation page.

  • Photograph of 10 Series® Wireless

    Omron

    10 Series® Wireless

    BP7450

    Alt names: HEM-7320

    Sizes: Adult (22-42 cm)

    Validation Protocol(s): ANSI/AAMI/ISO 81060-2: 2009

     

  • Photograph of 3 Series®

    Omron

    3 Series®

    BP7100

    Alt names: HEM-7311

    Sizes: Adult (22-42 cm)

    Validation Protocol(s): ANSI/AAMI/ISO 81060-2: 2009

     

  • Photograph of 5 Series®

    Omron

    5 Series®

    BP7200

    Alt names: HEM-7311

    Sizes: Adult (22-42 cm)

    Validation Protocol(s): ANSI/AAMI/ISO 81060-2: 2009

     

 

  • Photograph of 5 Series® Wireless

    Omron

    5 Series® Wireless

    BP7250

    Alt names: HEM-7311

    Sizes: Adult (22-42 cm)

    Validation Protocol(s): ANSI/AAMI/ISO 81060-2: 2009

     

  • Photograph of 7 Series® Wireless

    Omron

    7 Series® Wireless

    BP7350

    Alt names: HEM-7320

    Sizes: Adult (22-42 cm)

    Validation Protocol(s): ANSI/AAMI/ISO 81060-2: 2009

     

 

  • Photograph of Advanced Manual Inflate Blood Pressure Monitor

    A&D Medical

    Advanced Manual Inflate Blood Pressure Monitor

    UA-705

    Alt names: UA-705V, UA-704

    Sizes: Medium (23.8-36 cm), Large (36-45 cm)

    Validation Protocol(s): BHS Revised Protocol: 1993 *

  • Photograph of Bronze Upper Arm

    Omron

    Bronze Upper Arm

    BP5100

    Alt names: HEM-7311

    Sizes: Adult (22-42 cm)

    Validation Protocol(s): ANSI/AAMI/ISO 81060-2: 2009

     

 

 

 

 

 

  • Photograph of Complete™ Wireless

    Omron

    Complete™ Wireless

    BP7900

    Alt names: HEM-7311

    Sizes: Adult (22-42 cm)

    Validation Protocol(s): ANSI/AAMI/ISO 81060-2: 2009

     

 

  • Photograph of Gold Upper Arm

    Omron

    Gold Upper Arm

    BP5350

    Alt names: HEM-7311

    Sizes: Adult (22-42 cm)

    Validation Protocol(s): ANSI/AAMI/ISO 81060-2: 2009

     

 

  • Photograph of Platinum Upper Arm

    Omron

    Platinum Upper Arm

    BP5450

    Alt names: HEM-7311

    Sizes: Adult (22-42 cm)

    Validation Protocol(s): ANSI/AAMI/ISO 81060-2: 2009

     

 

 

  • Photograph of Silver Wireless

    Omron

    Silver Wireless

    BP5250

    Alt names: HEM-7320

    Sizes: Adult (22-42 cm)

    Validation Protocol(s): ANSI/AAMI/ISO 81060-2: 2009

     

 

  • Photograph of Talking+ Blood Pressure Monitor

    A&D Medical

    Talking+ Blood Pressure Monitor

    UA-1030T

    Alt names: UA-1020

    Sizes: Small (16-24 cm), Medium (23-37 cm), Large (31-45 cm), Smooth Fit (23-37 cm)

    Validation Protocol(s): BHS Revised Protocol: 1993 *

     

  • Photograph of ULTRACONNECT Wireless Blood Pressure Monitor

    A&D Medical

    ULTRACONNECT Wireless Blood Pressure Monitor

    UA-1200BLE

    Sizes: Integrated (22-42 cm)

    Validation Protocol(s): ANSI/AAMI/ISO 81060-2: 2009

     

 

 

  • Photograph of Welch Allyn Home® Blood Pressure Monitor, 1700 Series

    Hillrom-Welch Allyn

    Welch Allyn Home® Blood Pressure Monitor, 1700 Series

    H-BP100SBP

    Sizes: XS (15-24 cm), Standard (22-42 cm), XL (40-54 cm)

FDA flags 428 spinal cord stimulator patient deaths, urges more tests before implant

FDA flags 428 spinal cord stimulator patient deaths, urges more tests before implant

https://www.medtechdive.com/news/fda-flags-428-spinal-cord-stimulator-patient-deaths-urges-more-tests-befor/584714/

  • FDA on Thursday published a letter to healthcare providers outlining hundreds of reports of deaths and thousands of injuries and malfunctions with spinal cord stimulators, reminding physicians to follow product labels calling for a simulation in patients prior to permanently implanting the SCS devices.
  • Healthcare providers are supposed to trial the estimated 50,000 devices implanted each year from companies such as Abbott, Boston Scientific, Medtronic and Nevro to ensure they adequately relieve a patient’s pain. An agency review of 107,728 adverse event reports submitted in the last four years found 30,321 reports of unsatisfactory pain relief.
  • The warning comes after a June report from Public Citizen called for FDA to tighten how it regulates the devices, including requiring original PMA submissions for all new models and reassessing whether any approved devices should be removed from the market. Device Events is also among the organizations that have highlighted dangers with spinal cord stimulators. 

Dive Insight:

The labels on spinal cord stimulators are clear on the need for trial simulation periods: Materials from Abbott, Boston Scientific, Medtronic and Nevro state their devices are only for use in patients who received effective pain relief during trial stimulation. The companies also provide information on how to carry out these trial periods. Nevro, for example, provides pages of information for physicians on two different approaches to trial-phase implantation.  

Yet, FDA is concerned about compliance with the trial-phase requirement. After its dive into the data found 28% of MDRs cite “pain relief, inadequate” as a problem, FDA said the review “highlights the need for patients to undergo and demonstrate an adequate trial.” The next two most frequently cited Patient Problem Codes — “pain” and “therapeutic effects, unexpected” — also point to the possibility that some physicians may be implanting SCSs without performing trial periods. 

FDA also looked at the most frequently reported Device Problem Codes but appeared less concerned by the findings. “Charging problems” was the most commonly reported code, leading FDA to state the reports “are consistent with those expected with battery-powered stimulation devices intended for longer-term implantation and therapy.”

The 107,728 MDRs received by FDA in the four-year period following July 27, 2016, include reports of 428 individual deaths of patients implanted with SCSs between 2005 and 2020. Almost one-third of cases where times to event were available happened in the 30 days after implantation. Many of the patients had comorbidities and the average age was 69 years. FDA said MDRs often lack “enough information to establish a causal relationship between the device and the reported event.”

For now, FDA has limited its response to the data to a reminder of the need to trial SCS implants and recommendations for physicians about discussing the risks with patients and creating individualized follow-up plans for each recipient of a device. It also said it continues to evaluate the devices via mandated postmarket studies, medical literature and other sources.

But FDA’s steps don’t meet critics’ demands. Public Citizen’s June report detailed what it called FDA’s “dangerously lax oversight of high-risk implantable medical devices.” Public Citizen accused FDA of granting premarket approval to SCSs on the strength of studies of other devices, rather than prospective clinical trials of the implants being submitted for review.

In light of that evidence, Public Citizen called for FDA to move SCSs devices to a higher risk class. The Public Citizen report did not specifically mention the potential for harm due to a failure to follow the requirements on trial periods.

Coronavirus: Health experts join global anti-lockdown movement

Coronavirus: Health experts join global anti-lockdown movement

https://www.bbc.com/news/health-54442386

Thousands of scientists and health experts have joined a global movement warning of “grave concerns” about Covid-19 lockdown policies.

Nearly 6,000 experts, including dozens from the UK, say the approach is having a devastating impact on physical and mental health as well as society.

They are calling for protection to be focused on the vulnerable, while healthy people get on with their lives.

The declaration has prompted warnings by others in the scientific community.

Critics have pointed out:

  • a more targeted approach could make it difficult to protect vulnerable people entirely
  • the risk of long-term complications from coronavirus mean many others are also at risk

But the movement – known as the Great Barrington Declaration – mirrors some of the warnings in a letter signed by a group of GPs in the UK.

Sixty-six GPs, including TV doctors Dr Phil Hammond and Dr Rosemary Leonard and a number of medics who have held senior roles at the British Medical Association, have written to the health secretary, saying there is insufficient emphasis on “non-Covid harms” in the decision-making.

What is the Great Barrington Declaration?

The movement started in the US.

And the declaration has now been signed by nearly 6,000 scientists and medical experts across the globe as well as 50,000 members of the public.

The UK-based experts who have signed it include:

  • Dr Sunetra Gupta, an epidemiologist at Oxford University
  • Nottingham University self-harm expert Prof Ellen Townsend
  • Edinburgh University disease modeller Dr Paul McKeigue

They say keeping the lockdown policies in place until a vaccine is available would cause “irreparable damage, with the underprivileged disproportionately harmed”.

The health harms cited include:

  • lower childhood vaccination rates
  • worsening care for heart disease and cancer patients

And they point out the risk from coronavirus is 1,000 times greater for the old and infirm, with children more at risk from flu than Covid-19.

As immunity builds in the population, the risk of infection to all – including the vulnerable – falls, they say.

And this would be a much more “compassionate” approach.

The declaration recommends a number of measures to protect the vulnerable, including regular testing of care-home workers, with a move as far as possible towards using staff who have acquired immunity.

Retired people living at home should have groceries and other essentials delivered, it says.

And when possible, they should meet family members outside rather than inside.

Simple hygiene measures, such as hand washing and staying home when sick, should be practised by everyone.

But:

  • young low-risk individuals should be allowed to work normally
  • schools and universities should be open for in-person teaching
  • sports and cultural activities could resume and restaurants reopen

What do other experts say?

While clearly “well intentioned”, the declaration has profound ethical, logistical and scientific flaws, University of Leeds school of medicine associate professor Dr Stephen Griffin says.

The vulnerable come from all walks of life and deserve to be “treated equally”.

And “long Covid” is reported to have left even people mild infections with problems such as fatigue and joint pain for months.

University of Reading cellular biology expert Dr Simon Clarke, meanwhile, says whether herd immunity is even achievable remains unclear.

“Natural, lasting, protective immunity to the disease would be needed,” he says.

“And we don’t know how effective or long-lasting people’s post-infection immunity will be.”

Some say the most likely scenario is immunity is not long-term but future reinfections then become milder.

Local officials seeing increase in fentanyl-related crimes, deaths

obviously this reporter and/or the person she is talking to… seems to believe that there is only ONE FENTANYL but according to Wikipedia… there is some 1400 different analogs of Fentanyl and one analog Fentanyl Citrate is a C-II med approved for human use.  All other analogs are ILLEGAL OPIATES.

This article bounces back and forth between legal and illegal fentanyl analogs… as if there is only ONE FENTANYL ANALOG

Too bad that truth is not a ideal that many in public office and many reporters

 

 

 

Local officials seeing increase in fentanyl-related crimes, deaths

https://www.owensborotimes.com/news/2020/10/local-officials-seeing-increase-in-fentanyl-related-crimes-deaths/

Local law enforcement officials said they have seen more fentanyl across Owensboro and Daviess County in recent months, while the Daviess County Coroner’s Office said fentanyl-related deaths have also increased in 2020.

Officials said fentanyl — a substance used to treat severe pain — is being cut into fake prescription opioid pills, causing those who ingest them to overdose and in severe cases die.

According to National Institutes of Health Order Publications, fentanyl is a powerful synthetic opioid analgesic that is similar to morphine but is 50 to 100 times more potent. It is a Schedule II prescription drug.

County Coroner Jeff Jones said his office has seen a definite uptick in fentanyl-related deaths this year.

“We’ve had 3-4 cases this past year that have been fentanyl-related,” Jones said. “Compared to previous years, that’s an increase.”

Meanwhile, Owensboro Police Department Public Information Officer Andrew Boggess said OPD has been seeing an increase of fentanyl use and possession for five months straight.

Daviess County Sheriff’s Office Chief Deputy Major Barry Smith said his department saw a small increase of fentanyl — mainly due to a methamphetamine supply decrease stemming from COVID-19 and travel restrictions — earlier in the year.

“The danger continues of counterfeit pain medicine that could contain fentanyl and fentanyl-laced illicit drugs,” he said.

Unlike other drugs, fentanyl isn’t normally taken by itself. Instead, other drugs such as heroin and methamphetamine are often laced with trace amounts of it. According to Foundation for a Drug-Free World, a dose of fentanyl is considered to be lethal at 3 milligrams, compared to 30 milligrams of heroin.

Now, pills are being altered with the deadly substance, Boggess said. When OPD first noticed the increase of fentanyl and other similar drugs in the area, a press release was sent out to local news outlets warning the community about the issue.

“We have multiple cases open and ongoing pertaining to overdoses,” Boggess said. “There are a lot of investigations going on right now with overdoses where a person may have taken pills and not known what they were made of. It’s concerning because these overdoses can be fatal.”

Jones said the vast majority of toxicology reports pertaining to those who’ve died of a fentanyl overdose have contained multiple drugs.

“It’s hard to know if they’re laced with fentanyl, if it’s a combination of drugs,” he said. “Fentanyl is the primary cause of death in all of these cases.”

Boggess said OPD officers have begun carrying naloxone nasal spray, or Narcan, and it has prevented a number of overdoses from turning deadly.

“With overdoses, timing is extremely crucial,” he said.

Boggess also said OPD isn’t sure at this time where the fentanyl-laced pills are coming from. In Owensboro and Daviess County, methamphetamine laced with fentanyl has been believed to have been primarily manufactured by the Mexican cartel.

Though OPD has not seen a significant decrease in fentanyl-laced meth, the primary concern this time around is the frequency in which fentanyl has been discovered across the community.

“An important distinction here is, these pills are being purchased on the street level, not at the pharmacy,” Boggess said. “You don’t ever know what you’re really getting. It’s extremely potent in small quantities.”

 

Cerebrospinal Fluid Leak After Nasal Swab Testing for Coronavirus Disease 2019

Cerebrospinal Fluid Leak After Nasal Swab Testing for Coronavirus Disease 2019

https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2771362

In March 2020, coronavirus disease 2019 (COVID-19) emerged as a global pandemic. Testing for presence of active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is 1 pillar of the global response.1 In particular, nasopharyngeal, anterior nasal, and midturbinate swabs are 3 of the 5 methods for initial diagnostic specimen collection recommended by the US Centers for Disease Control and Prevention (CDC).2 However, complications associated with nasal swab testing are not well characterized. We describe the first case of a cerebrospinal fluid (CSF) leak after nasal testing for COVID-19, to our knowledge.

Report of a Case

A woman in her 40s presented with unilateral rhinorrhea, metallic taste, headache, neck stiffness, and photophobia. The patient had recently completed nasal COVID-19 testing for an elective hernia repair. Shortly after, she developed unilateral rhinorrhea, headache, and vomiting. The patient’s medical history was notable for idiopathic intracranial hypertension and removal of nasal polyps over 20 years before presentation. Physical examination revealed clear rhinorrhea from the right side. Flexible nasopharyngoscopy revealed a mass in the right anterior middle meatus, but did not identify the source of the fluid. The nasal drainage tested positive for β2-transferrin. Computed tomography (CT) and magnetic resonance imaging (MRI) identified a 1.8-cm encephalocele extending through the right ethmoid fovea into the middle meatus and a right sphenoid wing pseudomeningocele. Comparing these images to findings on CT performed in 2017 revealed that the encephalocele dated at least to that time (Figure 1). The 2017 CT diagnosis was paranasal sinus disease but not an encephalocele. The patient was admitted to the hospital for endoscopic surgical repair. At the beginning of the procedure, intrathecal fluorescein was infused through a lumbar drain. An encephalocele was identified in the right anterior ethmoid cavity (Figure 2). After reduction of the encephalocele, a skull base defect in the fovea ethmoidalis was repaired with a combination of acellular human dermal matrix and a poly(D,L-lactic) acid. The patient was admitted postoperatively for neurological monitoring and lumbar drain management.

Figure 1.  Imaging Prior to Cerebrospinal Fluid (CSF) Leak

Imaging Prior to Cerebrospinal Fluid (CSF) Leak

A, Brain computed tomographic image from 2017 in the coronal and sagittal planes demonstrating encephalocele situated over the fovea ethmoidalis prior to nasopharyngeal testing for COVID-19. The arrowhead demonstrates skull base defect. B and C, High-resolution magnetic resonance imaging (T2 sequence) in the sagittal plane during hospital admission in July 2020 after development of iatrogenic CSF leak. The yellow arrowheads indicate the encephalocele.

CVS: The pharmacy was 1,200 scripts behind and eight days behind in prescription refills

CVS Apologizes For Prescription Delays At Cape Stores

https://patch.com/massachusetts/falmouth/cape-residents-angry-cvs-falling-behind-prescriptions

FALMOUTH, MA — Cape Cod residents reported there have been delays refilling prescriptions at CVS Pharmacy locations in East Falmouth and Mashpee.

According to the Cape Cod Times, several residents complained that both pharmacies were behind on filling new prescriptions and refilling existing ones. Mashpee resident Lorri Landers told the Times a pharmacist told her the pharmacy was 1,200 scripts behind and eight days behind in prescription refills. She also accused the Mashpee CVS of violating the Health Insurance Portability and Accountability Act, alleging the pharmacists called out her prescriptions by name in front of eight people.

Matt Blanchette, a CVS spokesperson, apologized for the delays and said they were isolated to those two Cape Cod pharmacies. Blancette also said privacy with patient information is part of the company’s policies, so any potential HIPAA violation will be investigated.

“We had experienced prior temporary delays at these locations but have added additional resources and are accepting new prescription(s) in both locations,” Blanchette told the Cape Cod Times. “We plan to avoid any future disruption, and apologize for any delay.”

RUMOR ON THE STREET

Silver Scripts Part D is going to drop independent pharmacies from their preferred network beginning with next year’s program.